Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea
Background/Aims Little is known about the clinical characteristics and treatment outcomes of ST-segment elevation myocardial infarction (STEMI) in Korea during the coronavirus disease 2019 (COVID-19) era. We aimed to evaluate the clinical characteristics and treatment outcomes of patients with STEMI...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2022-07-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://kjim.org/upload/pdf/kjim-2022-077.pdf |
| _version_ | 1811324289511587840 |
|---|---|
| author | Seok Oh Myung Ho Jeong Kyung Hoon Cho Min Chul Kim Doo Sun Sim Young Joon Hong Ju Han Kim Youngkeun Ahn |
| author_facet | Seok Oh Myung Ho Jeong Kyung Hoon Cho Min Chul Kim Doo Sun Sim Young Joon Hong Ju Han Kim Youngkeun Ahn |
| author_sort | Seok Oh |
| collection | DOAJ |
| description | Background/Aims Little is known about the clinical characteristics and treatment outcomes of ST-segment elevation myocardial infarction (STEMI) in Korea during the coronavirus disease 2019 (COVID-19) era. We aimed to evaluate the clinical characteristics and treatment outcomes of patients with STEMI in the COVID-19 era. Methods A total of 588 consecutive patients with STEMI who underwent primary percutaneous coronary intervention were included in this study. The patients were categorized into the COVID-19 (from January 20, 2020 to December 31, 2020) and control groups (from January 20, 2019 to December 31, 2019). Results The COVID-19 group showed pre-hospital and in-hospital delays than the control group. The control group underwent more thrombus aspiration and had a higher proportion of left main coronary artery diseases, while the COVID-19 group had a higher proportion of multivessel diseases with a marked increase in the number and total length of stents than the control group. As for the prescribed medications, the COVID-19 group was administered more beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins than the control group. The clinical outcomes were comparable between the groups, except for higher incidences of atrioventricular block and temporary pacemaker implantation in the COVID-19 group. Conclusions Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion. |
| first_indexed | 2024-04-13T14:11:42Z |
| format | Article |
| id | doaj.art-10bee42ed3a74820a552859ba6a09ecf |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-13T14:11:42Z |
| publishDate | 2022-07-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-10bee42ed3a74820a552859ba6a09ecf2022-12-22T02:43:45ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482022-07-0137478679910.3904/kjim.2022.077170703Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South KoreaSeok Oh0Myung Ho Jeong1Kyung Hoon Cho2Min Chul Kim3Doo Sun Sim4Young Joon Hong5Ju Han Kim6Youngkeun Ahn7 Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea Department of Cardiology, Chonnam National University Hospital, Gwangju, KoreaBackground/Aims Little is known about the clinical characteristics and treatment outcomes of ST-segment elevation myocardial infarction (STEMI) in Korea during the coronavirus disease 2019 (COVID-19) era. We aimed to evaluate the clinical characteristics and treatment outcomes of patients with STEMI in the COVID-19 era. Methods A total of 588 consecutive patients with STEMI who underwent primary percutaneous coronary intervention were included in this study. The patients were categorized into the COVID-19 (from January 20, 2020 to December 31, 2020) and control groups (from January 20, 2019 to December 31, 2019). Results The COVID-19 group showed pre-hospital and in-hospital delays than the control group. The control group underwent more thrombus aspiration and had a higher proportion of left main coronary artery diseases, while the COVID-19 group had a higher proportion of multivessel diseases with a marked increase in the number and total length of stents than the control group. As for the prescribed medications, the COVID-19 group was administered more beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins than the control group. The clinical outcomes were comparable between the groups, except for higher incidences of atrioventricular block and temporary pacemaker implantation in the COVID-19 group. Conclusions Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion.http://kjim.org/upload/pdf/kjim-2022-077.pdfcovid-19percutaneous coronary interventionrepublic of koreast elevation myocardial infarctiontreatment outcome |
| spellingShingle | Seok Oh Myung Ho Jeong Kyung Hoon Cho Min Chul Kim Doo Sun Sim Young Joon Hong Ju Han Kim Youngkeun Ahn Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea The Korean Journal of Internal Medicine covid-19 percutaneous coronary intervention republic of korea st elevation myocardial infarction treatment outcome |
| title | Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea |
| title_full | Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea |
| title_fullStr | Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea |
| title_full_unstemmed | Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea |
| title_short | Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea |
| title_sort | treatment delay and outcomes of st segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the covid 19 era in south korea |
| topic | covid-19 percutaneous coronary intervention republic of korea st elevation myocardial infarction treatment outcome |
| url | http://kjim.org/upload/pdf/kjim-2022-077.pdf |
| work_keys_str_mv | AT seokoh treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT myunghojeong treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT kyunghooncho treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT minchulkim treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT doosunsim treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT youngjoonhong treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT juhankim treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea AT youngkeunahn treatmentdelayandoutcomesofstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionduringthecovid19erainsouthkorea |